Weekly docetaxel plus gemcitabine or vinorelbine in refractory advanced breast cancer patients: A parallel dose-finding study

Annals of Oncology

Volumn 11, Issue 3, 2000, Pages 367-371

  Frasci, G ^a   Comella, P ^a   D'Aiuto, G ^a   Thomas, R ^a   Capasso, I ^a   Elmo, M ^a   Botti, G ^a   Cortino, G R ^a   Lapenta, L ^a   De Rosa, V ^a   Vallone, P ^a   Petrillo, A ^a   Comella, G ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Breast cancer; Docetaxel + gemcitabine; Docetaxel + vinorelbine; Phase I

Indexed keywords

DOCETAXEL; GEMCITABINE; NAVELBINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE CALCULATION; DRUG EFFECT; DRUG TOLERABILITY; FEMALE; HUMAN; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SALVAGE THERAPY; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; PACLITAXEL; TAXOIDS; TREATMENT FAILURE; VINBLASTINE;

EID: 0033998108     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008346708604     Document Type: Article

References (15)

1. Flamm Honig S. Treatment of metastatic disease. In Harris JR, Hellman S, Henderson IC et al. (eds): Breast Diseases. Philadelphia, Pennsylvania: Lippincott 1996; 669-734.
2. Hoogstraten B, George SL, Samal B et al. Combination chemotherapy and adriamycin in patients with advanced breast cancer: A Southwest Oncology Group study. Cancer 1976; 38: 13-20.
3. Sedlacek SM. Salvage therapy for metastatic disease. Semin Oncol 1990; 17 (Suppl 7): 45-9.
4. Van Oosterom AT. Docetaxel (taxotere): An effective agent in the management of second-line breast cancer. Semin Oncol 1995; 22 (Suppl 13): 22-8.
5. Nabholtz JM, Senn HJ, Bezwoda WR et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. J Clin Oncol 1999; 17: 1413-24.
6. Jones S, Winer E, Vogel C et al. Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. J Clin Oncol 1995; 13: 2567-74.
7. Carmichel J, Possinger K, Phillip P et al. Advanced breast cancer: A phase II trial with gemcitabine. J Clin Oncol 1995; 13: 2731-6.
8. Escudero P, Bueso P, Mayordomo JI et al. Docetaxel + vinorelbine is an active combination for patients with anthracycline-refractory breast cancer. Results of a phase II trial. Proc Am Soc Clin Oncol 1998; 17: 139a.
9. De Paz L, Lluch A, Martin M et al. A phase II study of docetaxel and vinorelbine in metastatic breast cancer. Proc Am Soc Clin Oncol 1999; 18: 119.
10. Mavroudis D, Kouroussis Ch, Malamos N et al. A phase II trial of docetaxel and gemcitabine as second-line treatment in metastatic breast cancer. Proc Am Soc Clin Oncol 1998; 17: 158a.
11. Briasoulis E, Karavasilis V, Anastasopoulos D et al. Weekly docetaxel in minimally pretreated cancer patients: A dose-escalation study focused on feasibility and cumulative toxicity of long-term administration. Ann Oncol 1999; 10: 701-6.
12. Fumoleau P, Chevallier B, Kerbrat P et al. A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer. Report of the Clinical Screening group of the EORTC. Ann Oncol 1996; 7: 165-71.
13. Akerley W, Glantz M, Choy H et al. Phase I trial of weekly paclitaxel in advanced lung cancer. J Clin Oncol 1998; 16: 153-8.
14. Frasci G, D'Aiuto G, Comella P et al. Cisplatin epirubicin paclitaxel weekly administration in advanced breast cancer: A phase I study of the Southern Italy Cooperative Oncology Group. Breast Cancer Res Treat 1999; 56: 239-52.
15. Valero V, Jones SE, Von Hoff DD et al. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin Oncol 1998; 16: 3362-8.